Hypoglycemia, a dangerous drop in blood glucose levels related to insulin and sulfonylurea (SU) use, has been identified as one of the top three preventable adverse drug events by the U.S. Department of Health and Human Services. Yet the prevalence and high burden of disease in patients with type 2 diabetes (T2D), particularly the elderly, are often underappreciated in clinical settings. Supporting the early identification and management of those at greatest risk is critical.
The Endocrine Society has made reducing the incidence of hypoglycemia a priority for a number of years. The Hypoglycemia Prevention Initiative is a multi-year joint effort of the Endocrine Society and Avalere Health to determine best practices in primary care to reduce the impact of hypoglycemia on older (65+) people with type 2 diabetes (T2D) who use insulin and/or sulfonylurea, have a recent A1c <7%, and are at increased risk of hypoglycemia. To learn more, visit the Hypoglycemia Prevention Initiative page.
We empower high-quality, equitable healthcare for people with hormone health conditions, including diabetes and obesity, infertility, thyroid conditions, osteoporosis, and hormone-related cancers. Together, we promote an environment that helps people of all backgrounds and ethnicities access the medical care they need.
Join our endocrine community and become a member! Only members receive access to a variety of member benefits that will enhance your career. If your membership has lapsed, rejoin today so that you can continue to receive your membership benefits.